DEA Schedule III Deadline June 22: What California M-License Holders Must Do Now
California medical cannabis operators are 18 days away from a federal deadline that will determine whether they can continue operating under their state license while the DEA processes a new federal registration. The filing window closes on or about June 22, 2026, and missing it carries consequences that no California licensee can afford to ignore.
By the Baghoomian Law team
The April 23 Order: A Narrow but Consequential Rescheduling
On April 23, 2026, the U.S. Department of Justice and Drug Enforcement Administration issued a long-anticipated final order moving certain marijuana products from Schedule I to Schedule III of the Controlled Substances Act. The order was published in the Federal Register on April 28, 2026, in two companion notices addressing FDA-approved cannabis-derived drug products and state-licensed medical marijuana.
The scope is narrower than many headlines suggested. The order applies to FDA-approved cannabis products and to qualifying state-licensed medical cannabis programs. It does not legalize adult-use cannabis at the federal level, and California adult-use (A-designated) activity remains federally illegal under the Controlled Substances Act. For California operators, the practical effect of the order is that the medicinal side of the state's bifurcated market now has, for the first time, a path to operate within an authorized federal Schedule III framework, provided operators take affirmative steps to enter that framework.
The DEA opened its Medicinal Marijuana Dispensary Registration Portal and began accepting applications on April 29, 2026, the day after Federal Register publication. The annual application fee is $794 and is non-refundable.
Why June 22 Is the Deadline That Matters
Tucked inside the rescheduling framework is a 60-day window measured from Federal Register publication. State-licensed medical marijuana businesses that file a complete DEA registration application within that window — running through approximately June 22, 2026 — receive two important protections that later filers do not. First, they qualify for what the agency has described as interim operating authority, which permits continued operation under the existing state license while the DEA reviews the federal application. Second, the DEA has signaled that early-window applications will be processed on an expedited timeline, with the agency aiming to act within roughly six months.
Operators who file after June 22 do not lose the ability to register, but they lose those protections. Late applicants face the prospect of a gap between the effective date of any federal enforcement posture and the date their DEA registration is granted — a gap during which their continued operation could be exposed to greater federal risk and during which review timelines are not guaranteed. For an operator running a manufacturing line, a distribution operation, or a medical retail storefront, that gap is not a technicality. It is an operational risk that demands a deliberate compliance choice this month, not next quarter.
California's Response: DCC Emergency Rulemaking and Form 27
California regulators did not wait for the dust to settle. On May 18, 2026, the Department of Cannabis Control issued DCC-2026-03-E: Modifications to A and M Designation, an emergency rulemaking that addresses one of the structural awkwardnesses of California's licensing scheme in light of federal rescheduling. Under existing law, many California licensees hold a single license carrying both Adult-Use (A) and Medicinal (M) designations. The emergency action would allow those holders to be issued separate A and M licenses on an expedited basis, and, where certain requirements are met, to have the new M license issued to a different legal entity. The Office of Administrative Law accepted public comment from May 27 through May 31, 2026, and the rule is moving through the emergency adoption process.
The separation matters because, under federal law, the new Schedule III status attaches only to qualifying state-licensed medicinal activity. Operators who want to capture the benefits of federal rescheduling for their M-side activity, while continuing their A-side business with appropriate corporate and operational separation, need a regulatory vehicle to do so. The emergency rule is intended to be that vehicle.
In parallel, DCC has streamlined its licensing-change process through its Federal Rescheduling Resources page. Cultivation licensees no longer need to wait until renewal to request a change of designation. DCC has also eliminated the requirement for a new local authorization where the request is to change a license to an M-only designation, or to add an M-designation to an existing A license. Requests are submitted via Form 27: Notifications and Requests to Modify a License, filed by the Designated Responsible Party from the email address on file with DCC and sent to licensechange@cannabis.ca.gov. Critically, licensees must continue operating under their current designation until DCC approves the request — paper filings do not, by themselves, change operating authority.
A Bifurcated Federal World: What Stays Risky for A-License Operators
California's adult-use operators should not read the rescheduling order as a green light. The Schedule III change does not touch A-designated activity, and recreational cannabis remains a Schedule I substance under federal law. Section 280E of the Internal Revenue Code, which denies most ordinary business deductions to sellers of Schedule I and Schedule II controlled substances, continues to apply to A-side operations. For operators with mixed A and M activity, the post-rescheduling planning question is no longer abstract: should a portion of the business be separated into a properly structured M-only entity that can pursue DEA registration, claim federal tax treatment more aligned with conventional businesses, and access certain regulated medical channels?
Those choices have real costs and trade-offs — corporate restructuring, intercompany agreements, lease assignment or sublease analysis, financing covenant review, local-jurisdiction notice obligations, and labor-side considerations under any project labor or labor-peace agreement. They are not decisions to be made on a press-release timeline. But they are decisions that must be analyzed now, because the window to capture interim operating authority on the M side closes in less than three weeks.
What This Means for Operators
The practical compliance picture for the next 18 days has three layers. First, any California licensee that currently holds an M-designation or a dual A/M designation and intends to participate in the federal Schedule III framework should be working this week on a complete DEA registration package, with the goal of filing through the DEA portal before June 22, 2026. The application requires careful diligence on ownership disclosures, security and recordkeeping representations, and accuracy in the description of state-licensed activity. Incomplete or inaccurate filings will not qualify for interim operating authority.
Second, operators with dual A/M licenses who want to pursue separation should be tracking DCC's emergency rule and preparing the corporate, real estate, and operational records that an expedited Form 27 process will require. Separation analysis should include a 280E modeling exercise so the operator understands the federal tax impact before, not after, the entity structure is changed.
Third, A-only operators and operators who do not intend to enter the federal program need to understand what has not changed. Federal illegality, banking constraints, and 280E remain. The April 23 order does not alter California's local-control framework, its Title 4, Division 19 regulations, or the enforcement posture of the Unified Cannabis Enforcement Taskforce, which continues to pursue unlicensed activity across the state.
A more aggressive federal rescheduling — covering marijuana as a whole rather than only FDA-approved and state-licensed medical activity — remains a live issue. The DEA has scheduled an expedited hearing to commence June 29, 2026, to consider that broader question. The outcome of that hearing will materially shape what compliant operations look like in 2027 and beyond. For now, however, the immediate compliance task is the one with the June 22 deadline.
Talk to Counsel Before the Window Closes
Decisions about whether to register with the DEA, how to restructure a dual-license operation, and how to position your business for the next phase of federal cannabis policy are fact-specific and reversible only at significant cost. If your operation includes an M-designation or you are evaluating entry into the federal Schedule III framework, the team at Baghoomian Law can help you assess the registration application, structure the corporate and licensing changes that California's emergency rule contemplates, and align your filings on both the federal and state tracks. Contact us at dcclicensing.com to schedule a consultation before the June 22, 2026 deadline.
This post is for informational purposes only and does not constitute legal advice. Consult licensed counsel for advice on your specific situation.
